VNDA News and Press, Vanda Pharmaceuticals Inc.

2024-05-15 11:26:48 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Call Transcript Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals GAAP EPS of -$0.07, revenue of $47.46M Vanda Pharmaceu...

Vanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness PR Newswire • New Drug Application expected to be submitted in Q4 2024 WASHINGTON , May 15, 2024 /PRNewswire/ -- Vanda Pharmaceuticals In...

2024-05-08 21:48:11 ET Vanda Pharmaceuticals, Inc. (VNDA) Q1 2024 Earnings Conference Call May 08, 2024 04:30 pm ET Company Participants Mihael Polymeropoulos - President, Chairman and CEO Kevin Moran - CFO Tim Williams - Senior Vice President and General Counsel...

Vanda Pharmaceuticals Reports First Quarter 2024 Financial Results PR Newswire Revenues for Q1 2024 were $47.5 million , an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt ® approved fo...

Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak PR Newswire No Shareholder Action Required at This Time WASHINGTON , May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq:...

2024-05-07 11:13:48 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...

Vanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024 PR Newswire Conference Call and Webcast to Follow WASHINGTON , April 30, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will r...

Reminds Vanda’s Board of Their Fiduciary Duties Given the Mishandling of Future Pak’s Offer to Acquire Vanda’s Underperforming and Undervalued Shares at an ~80-90% Premium Expresses Serious Concerns Over Entrenchment, Misaligned Incentives, and Cronyism at Vanda, Incl...

Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation PR Newswire WASHINGTON , April 22, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Supreme Court denied Va...

2024-04-22 10:55:53 ET More on Vanda Pharmaceuticals Vanda Pharmaceuticals: Fanapt Bipolar Win Doesn't Change Much Vanda Pharmaceuticals' Portfolio Likely Has Upside From 2024 Approvals, Underpinned By Cash Vanda Pharmaceuticals Inc. (VNDA) Q4 2023 Earnings Call Tran...